** Shares of Boston-based drug developer PepGen PEPG.O fall 9% to $2.56 premarket
** Company says it will temporarily pause mid-stage study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD)
** Says the study is paused until company can review results from patient group dosed with 10 mg/kg, which is expected during Q3
** DMD is a genetic disorder causing progressive muscle weakness and degeneration
** Company says no new safety issues related to PGN-EDO51 have been observed since the company's last safety update in January
** PEPG has fallen 83% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。